LSE:AZNPharmaceuticals
AstraZeneca’s China Bet Recasts Growth Story Around Obesity And Diabetes
AstraZeneca (LSE:AZN) has announced a $15b investment in China focused on R&D and manufacturing.
The plan includes building end to end cell therapy capabilities and expanding local partnerships with Chinese and UK institutions.
The company has also agreed a new partnership with CSPC Pharmaceuticals to develop obesity and diabetes treatments using AI driven discovery and once monthly dosing platforms.
AstraZeneca, a global biopharmaceutical group focused on oncology, cardiovascular, renal,...